Nearly half of NCR residents not sold on COVID vaccine

    Complying. Manila residents returning from the provinces where they spent the holidays undergo free rapid COVID testing at the Quirino Grandstand in compliance with the order issued by Mayor Isko Moreno. PHOTO BY RHOY COBILLA

    AMID the global scramble to secure vaccine supplies, almost half of Filipinos in Metro Manila are unsure about getting inoculated versus the coronavirus disease (COVID-19).

    According to a survey conducted by the independent OCTA Research Team, less than 50 percent of the 600 respondents who participated said they are still undecided if they want to be given COVID-19 vaccines.

    “Survey results also show that 47 percent of respondents in Metro Manila have indicated that they were not able to decide if they will have themselves vaccinated,” said the OCTA team.

    In addition, 28 percent of the respondents have answered that they will not have themselves vaccinated against the novel virus.

    On the other hand, the survey shows that only 25 percent of Metro Manila respondents are willing to get vaccinated with the COVID-19 vaccine.

    Among the ABC classes, 52 percent are undecided, 29 percent are willing to be vaccinated, and 19 percent refuse to be vaccinated.

    For class D, 48 percent are undecided, 28 percent are not willing to be vaccinated, and 24 percent agree to be vaccinated.

    And for class E, 42 percent are undecided, 31 percent are unwilling to be vaccinated, and 27 percent are willing to be vaccinated.

    According to the OCTA team, the independent and non-commissioned survey was conducted in the NCR from December 9 to 13, 2020 using face-to-face interviews with a sample size of 600 respondents that are aged 18 and above.

    The survey, which has a sampling error of +4%, asked respondents about their willingness to get vaccinated against the COVID-19 virus.

    And while Filipinos ponder over getting inoculated, the Department of Health (DOH) yesterday bared that the forthcoming clinical trials for the candidate COVID-19 vaccine of pharmaceutical firm Janssen will be taking place in 5 sites.

    In a television interview, Health Undersecretary Maria Rosario Vergeire said the Vaccine Expert Panel (VEP) has already assigned five sites where the clinical trial will be conducted.

    “We have five assigned sites for Janssen that will be announced in the coming days, said Vergeire.

    It was back in late December when Janssen became the first COVID-19 vaccine manufacturer to be authorized by the Food and Drug Administration (FDA) to conduct clinical trials in the country.

    The applications for Phase 3 clinical trials of Sinovac Biotech Ltd., Clover Pharmaceuticals, and Gamaleya Research Institute are still under evaluation.